TY - JOUR
T1 - Outcomes of 1,639 hepatectomies for non-colorectal non-neuroendocrine liver metastases
T2 - a multicenter analysis
AU - on behalf of the Japanese Society of Hepato-Biliary-Pancreatic Surgery
AU - Sano, Keiji
AU - Yamamoto, Masakazu
AU - Mimura, Tetsushige
AU - Endo, Itaru
AU - Nakamori, Shoji
AU - Konishi, Masaru
AU - Miyazaki, Masaru
AU - Wakai, Toshifumi
AU - Nagino, Masato
AU - Kubota, Keiichi
AU - Unno, Michiaki
AU - Sata, Naohiro
AU - Yamamoto, Junji
AU - Yamaue, Hiroki
AU - Takada, Tadahiro
N1 - Funding Information:
Acknowledgments This study is supported in part by the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED. We would like to express many thanks to board-certified training institutions of JSHBPS that registered data of non-colorectal non-neuroendocrine liver metastases (decreasing order of registered cases, registered number was no less than 20 cases shown in parenthesis): Masakazu Yamamoto, Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University Hospital (77), Tetsushige Mimura, Department of Surgery, Okayama Saiseikai General Hospital (73), Itaru Endo, Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine (56), Shoji Nakamori, Department of Hepatobiliary-Pancreatic Surgery, National Hospital Organization Osaka National Hospital (55), Masaru Konishi, Department of Hepatobiliary-Pancreatic Surgery, National Cancer Center Hospital East (50), Masaru Miyazaki, Department of General Surgery, Graduate School of Medicine, Chiba University (46), Toshifumi Wakai, Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences (40), Masato Nagino, Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine (35), Keiichi Kubota, Second Department of Surgery, Dokkyo Medical University (33), Michiaki Unno, Department of Surgery, Tohoku University Graduate School of Medicine (33), Naohiro Sata, Department of Surgery, Jichi Medical University (32), Junji Yamamoto, Department of Surgery, National Defense Medical College (31), Takeyuki Misawa, Department of Surgery, Jikei University Kashiwa Hospital (29), Hiroyuki Nitta, Department of Surgery, Iwate Medical University (29), Chie Kitami, Department of Surgery, Nagaoka Chuo General Hospital (29), Nobuhiro Ohkohchi, Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, University of Tsukuba (29), Satoshi Hirano, Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine (28), Yasuhiro Shimizu, Department of Gastroenterological Surgery, Aichi Cancer Centre Hospital (28), Yasuji Seyama, Department of Surgery, Tokyo Metropolitan Bokutoh Hospital (28), Takehito Otsubo, Division of Gastroenterological and General Surgery, St. Marianna University School of Medicine (26), Toru Mizuguchi, Department of Surgery, Surgical Oncology and Science, Sapporo Medical University (26), Masaji Tani, Division of Gastrointestinal, Breast and General Surgery, Department of Surgery, Shiga Medical University (26), Tadatoshi Takayama, Department of Digestive Surgery, Nihon University School of Medicine (25), Etsuro Hatano, Department of Surgery, Graduate School of Medicine, Kyoto University (25), Hiroshi Yokomizo, Department of Surgery, Japanese Red Cross Kumamoto Hospital (23), Hidetoshi Eguchi, Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University (23), Shigehiro Shiozaki, Department of Gastroenterological Surgery, Hiroshima City Hiroshima Citizens Hospital (22), Kazumitsu Ueda, Department of Surgery, Hitachi General Hospital (22), Syoji Kubo, Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine (22), Kengo Fukuzawa, Department of Surgery, Oita Red Cross Hospital (22), Koji Okuda, Department of Surgery, Kurume University School of Medicine (21), Takashi Kaiho, Department of Surgery, Kimitsu Chuo Hospital (21), Takuya Nakai, Department of Surgery, Kindai University Faculty of Medicine (21), Mitsuo Shimada, Department of Digestive and Transplant Surgery, Tokushima University (20), Masahiko Murakami, Department of Gastroenterological and General Surgery, Showa University (20), and other 89 institutions.
Publisher Copyright:
© 2018 Japanese Society of Hepato-Biliary-Pancreatic Surgery
PY - 2018/11
Y1 - 2018/11
N2 - Background: Whether non-colorectal non-neuroendocrine liver metastasis (NCNNLM) should be treated surgically remains unclear. Methods: Data regarding 1,639 hepatectomies performed between 2001 and 2010 for 1,539 patients with NCNNLM were collected from 124 institutions. Patient characteristics, types of primary tumor, characteristics of liver metastases, and post-hepatectomy outcomes were analyzed. Results: The five most frequent primary tumors were gastric carcinoma (540 patients [35%]), gastrointestinal stromal tumor (204 patients [13%]), biliary carcinoma (150 patients [10%]), ovarian cancer (107 patients [7%]), and pancreatic carcinoma (77 patients [5%]). R0/1 hepatectomy was achieved in 90% of patients, with 1.5% in-hospital mortality rate. Overall and disease-free survival rates of 1,465 patients included in survival analysis were 41% and 21%, respectively, at 5 years, and 28% and 15%, respectively, at 10 years. Five-year survival associated with the five frequent primary tumors were 32%, 72%, 17%, 52%, and 31%, respectively, and factors predictive of a poor outcome differed by the primary tumor type. Conclusions: Our data indicated that hepatectomy is safe for NCNNLM and that patient prognoses vary depending on the type of primary tumors. Indications for hepatectomy should be determined with reference to survival rates and risk factors specific to each of the various types of primary tumor.
AB - Background: Whether non-colorectal non-neuroendocrine liver metastasis (NCNNLM) should be treated surgically remains unclear. Methods: Data regarding 1,639 hepatectomies performed between 2001 and 2010 for 1,539 patients with NCNNLM were collected from 124 institutions. Patient characteristics, types of primary tumor, characteristics of liver metastases, and post-hepatectomy outcomes were analyzed. Results: The five most frequent primary tumors were gastric carcinoma (540 patients [35%]), gastrointestinal stromal tumor (204 patients [13%]), biliary carcinoma (150 patients [10%]), ovarian cancer (107 patients [7%]), and pancreatic carcinoma (77 patients [5%]). R0/1 hepatectomy was achieved in 90% of patients, with 1.5% in-hospital mortality rate. Overall and disease-free survival rates of 1,465 patients included in survival analysis were 41% and 21%, respectively, at 5 years, and 28% and 15%, respectively, at 10 years. Five-year survival associated with the five frequent primary tumors were 32%, 72%, 17%, 52%, and 31%, respectively, and factors predictive of a poor outcome differed by the primary tumor type. Conclusions: Our data indicated that hepatectomy is safe for NCNNLM and that patient prognoses vary depending on the type of primary tumors. Indications for hepatectomy should be determined with reference to survival rates and risk factors specific to each of the various types of primary tumor.
KW - Cholangiocarcinoma
KW - Gastric carcinoma
KW - Hepatectomy
KW - Non-colorectal non-neuroendocrine liver metastasis
KW - Pancreatic carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85056729573&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056729573&partnerID=8YFLogxK
U2 - 10.1002/jhbp.587
DO - 10.1002/jhbp.587
M3 - Article
C2 - 30311741
AN - SCOPUS:85056729573
SN - 1868-6974
VL - 25
SP - 465
EP - 475
JO - Journal of Hepato-Biliary-Pancreatic Sciences
JF - Journal of Hepato-Biliary-Pancreatic Sciences
IS - 11
ER -